Ticker Details
Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat.
IPO Date:	July 31, 1996
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.2B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.11 | 2.90%
Avg Daily Range (30 D):	$0.06 | 3.78%
Avg Daily Range (90 D):	$0.04 | 3.00%

Institutional Daily Volume
Avg Daily Volume:	2.95M
Avg Daily Volume (30 D):	14.81M
Avg Daily Volume (90 D):	9.32M

Trade Size
Avg Trade Size (Sh.):	355
Avg Trade Size (Sh.) (30 D):	545
Avg Trade Size (Sh.) (90 D):	487

Institutional Trades
Total Institutional Trades:	2,847
Avg Institutional Trade:	$1.82M
Avg Institutional Trade (30 D):	$1.58M
Avg Institutional Trade (90 D):	$1.32M
Avg Institutional Trade Volume:	.63M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.23M
Avg Closing Trade (30 D):	$1.26M
Avg Closing Trade (90 D):	$1.09M
Avg Closing Volume:	810.88K

News

Dec 11, 2025 @ 1:00 PM Geron Corporation Announces Strategic Restructurin... Source: Harout Semerjian

Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire

Oct 23, 2025 @ 10:14 PM GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & S... Source: Bragar Eagel & Squire, P.C.

Oct 22, 2025 @ 12:00 PM Cassava Sciences Appoints Dawn C. Bir to the Board... Source: Cassava Sciences, Inc.

Oct 13, 2025 @ 8:34 PM Geron Corporation Announces Executive Leadership T... Source: Geron Corporation

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.12	$-.03	$-.02
Diluted EPS	$-.12	$-.03	$-.02
Revenue	$183.4M	$47.23M	$49.04M
Gross Profit
Net Income / Loss	$-79.99M	$-18.43M	$-16.38M
Operating Income / Loss	$-63.1M	$-13.89M	$-12.45M
Cost of Revenue
Net Cash Flow	$17.81M	$.39M	$-6.01M
PE Ratio